RxDoctor Payments DataLook up a doctor →

Jason Guichard

Advanced Heart Failure and Transplant Cardiology · Greenville, SCNPI 1902030877

Payments from drug & device makers

$4,315,754in general payments, 2019–2025

Across 627 payments — averaging $6883.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endotronix, Inc.$3.3M
  • AstraZeneca$335K
  • United Therapeutics Corporation$277K
  • Abbott$230K
  • Astrazeneca UK Limited$94K
  • Analog Devices Inc.$27K
  • plus $36K from 36 others

What the payments were for

  • Travel & lodging$8804%
  • Food & beverage$23,21793%
  • Education$8673%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,315,754 in reported general payments places this provider in the 95th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.

See all advanced heart failure and transplant cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$163,414
Medicare patients
888
Services billed
2,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis87$1,968,314
Tyvaso DpiTreprostinil48$1,139,751
VyndaqelTafamidis Meglumine15$298,744
EntrestoSacubitril/Valsartan365$282,420
JardianceEmpagliflozin213$253,226
OpsumitMacitentan20$252,701
CamzyosMavacamten30$248,943
Ambrisentan14$84,991
FarxigaDapagliflozin Propanediol91$68,578
EliquisApixaban62$66,289
XareltoRivaroxaban24$19,139
Sildenafil Citrate27$14,497
Torsemide231$4,913
Midodrine Hcl13$4,110
Spironolactone442$2,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$1,221$2,333,346164 claims
NovartisEntresto$810$282,420365 claims
Boehringer IngelheimJardiance$339$253,226213 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,065$252,70120 claims
E.r. Squibb & Sons, L.L.C.Camzyos$908$248,94330 claims
AstraZenecaFarxiga$335,330$68,57891 claims
Johnson & JohnsonXarelto$140$19,13924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.

Other advanced heart failure and transplant cardiology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →